Clinical Trial Details
— Status: Not yet recruiting
Administrative data
| NCT number |
NCT04401592 |
| Other study ID # |
ENDOGAL |
| Secondary ID |
|
| Status |
Not yet recruiting |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
September 1, 2021 |
| Est. completion date |
September 1, 2025 |
Study information
| Verified date |
May 2020 |
| Source |
Semmelweis University |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational [Patient Registry]
|
Clinical Trial Summary
Endometriosis is one of the most common infertility-related gynecologic disorder that affect
approximately 10-15% of women in reproductive age. The main symptoms are chronic pelvic pain,
infertility, dysmenorrhea and dyspareunia. There exists an average diagnostic delay of 7 year
but data widely varies between different countries. The current "gold standard" in the
diagnosis of endometriosis remains a laparoscopy. Since laparoscopy is an invasive surgical
procedure with its potential risk, the development of a non-invasive laboratory test would be
of great benefit in the early, clinical management of this diseaseIn the past few years,
lectins have become the focus of reproductive immunology, inflammation and autoimmunity.
Galectins (Gal) are beta-galactoside binding lectins that play a key role in the regulation
of the immune system, cell growth, adhesion, apoptosis, and angiogenesis. Until now 13
different types of galectins have been found in humans, among them Gal-1-4, 7-9 and 12 were
detected in the normal endometrium. So far only Gal-1 and Gal-3 have been studied in relation
to endometriosis. In a recent pilot study, the investigators have shown that Gal-9 levels are
significantly elevated in the serum of endometriosis patients compared to healthy controls.
Gal-9 had a high sensitivity (94%) and specificity (93,75%), indicating better diagnostic
potential than that of other endometriosis biomarkers and of surgery as the current gold
standard.
Description:
Endometriosis is one of the most common infertility-related gynecologic disorder that affect
approximately 10-15% of women in reproductive age. The main symptoms are chronic pelvic pain,
infertility, dysmenorrhea and dyspareunia. The etiology and pathogenesis of endometriosis has
been widely investigated over the past 30 years. Although there are several concepts trying
to explain its development, but none of them can be applied for all types of the disease.
The peak incidence of the diagnosis of endometriosis lies between the ages of 25 to 34,
although symptoms mostly develop much earlier. There exists an average diagnostic delay of 7
year but data widely varies between different countries: in the is UK 7.9 years, in the US
11.7 years, in Germany and Austria 7 years, in Spain 8 years, in Norway 6.7 years, in Ireland
and Belgium 5 years and in Hungary 3.9 years. Such a diagnostic delay is multifactorial, but
most importantly due to the lack of non-invasive diagnosis.
The current "gold standard" in the diagnosis of endometriosis remains a laparoscopy with a
sensitivity of 79% and a specificity of 94%. Since laparoscopy is an invasive surgical
procedure with its potential risk, the development of a non-invasive laboratory test would be
of great benefit in the early, clinical management of this disease. Such a biomarker has the
enormous potential to improve quality of life, reduce the risks to the patient and the
enormous costs to society related to endometriosis.
Until now, several molecules involved in the pathogenesis of endometriosis were investigated
as a potential biomarker, however the majority of them have proven inadequate for the
diagnosis. In the past few years, lectins have become the focus of reproductive immunology,
inflammation and autoimmunity. Galectins (Gal) are beta-galactoside binding lectins that play
a key role in the regulation of the immune system, cell growth, adhesion, apoptosis, and
angiogenesis. Until now 13 different types of galectins have been found in humans, among them
Gal-1-4, 7-9 and 12 were detected in the normal endometrium. So far only Gal-1 and Gal-3 have
been studied in relation to endometriosis. It was reported that Gal-1 had a cycle-dependent
expression in normal endometrial stromal cells, and its production was significantly elevated
in the early pregnancy decidua. In relation to endometriosis, Gal-1 was found to be more
abundantly expressed in ectopic endometriotic lesions when compared with the eutopic tissues.
Furthermore, the eutopic endometrium of the affected patients showed higher Gal-1 expression
than its normal counterparts. In addition to this, similar to Gal-1, Gal-3 was overexpressed
in various forms of endometriosis as well as in the eutopic endometrium of diseased women.
The investigators have previously shown that Gal-9 mRNA was markedly overexpressed in the
eutopic endometrium of patients with endometriosis in comparison with healthy controls. In
addition, the investigators results showed that besides the eutopic endometrium, Gal-9 was
also expressed in ectopic implants regardless of the localization of the lesions. The
investigators have determined that Gal-9 levels are significantly elevated in the serum of
endometriosis patients compared to healthy controls. Gal-9 has a high sensitivity (94%) and
specificity (93,75%), indicating better diagnostic potential than that of other endometriosis
biomarkers. The optimal cutoff point estimated from the Youden's index was 132 pg/mL, with a
sensitivity of 94% and specificity of 93.75%. Using this threshold, the positive predictive
value was 97.92% and the negative predictive value was 83.33%, with a prevalence of 75.76%.
The diagnostic accuracy of this test was 93.94%, indicating better diagnostic potential than
that other already published serum biomarkers.
Based on this previous results, the investigators suggest that Gal-9 is produced by ectopic
endometriotic implants, the investigators would like to determine the serum Gal-9 levels one
day before and after the surgery and at least 1-6 months later. The investigators aim is to
examine the serum Gal-1 and Gal-3 levels in endometriosis patients.
